Literature DB >> 18407333

Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer.

Bruce Montgomery1, Philip Lavori, Mark Garzotto, Kelvin Lee, Mary Brophy, Surai Thaneemit-Chen, William Kelly, Joseph Basler, Robert Ringer, Wei Yu, Alice Whittemore, Daniel W Lin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18407333     DOI： 10.1016/j.urology.2008.02.050

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  7 in total

Review 1.  Radical prostatectomy as primary treatment of high-risk prostate cancer.

Authors:  Alexandre Ingels; Alexandre de la Taille; Guillaume Ploussard
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

Review 2.  Contemporary management of high-risk localized prostate cancer.

Authors:  Mark Garzotto; Arthur Y Hung
Journal:  Curr Urol Rep       Date:  2010-05       Impact factor: 3.092

Review 3.  Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.

Authors:  Javier Puente; Enrique Grande; Ana Medina; Pablo Maroto; Nuria Lainez; Jose Angel Arranz
Journal:  Ther Adv Med Oncol       Date:  2017-03-01       Impact factor: 8.168

4.  An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.

Authors:  Emmanuel S Antonarakis; Daniel Keizman; Zhe Zhang; Bora Gurel; Tamara L Lotan; Jessica L Hicks; Helen L Fedor; Michael A Carducci; Angelo M De Marzo; Mario A Eisenberger
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

5.  Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life.

Authors:  G Ploussard; B Paule; L Salomon; Y Allory; S Terry; D Vordos; A Hoznek; F Vacherot; C-C Abbou; S Culine; A de la Taille
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-11-24       Impact factor: 5.554

6.  Genetic markers associated with early cancer-specific mortality following prostatectomy.

Authors:  Wennuan Liu; Chunmei C Xie; Christopher Y Thomas; Seong-Tae Kim; Johan Lindberg; Lars Egevad; Zhong Wang; Zheng Zhang; Jishan Sun; Jielin Sun; Patrick P Koty; A Karim Kader; Scott D Cramer; G Steven Bova; S Lilly Zheng; Henrik Grönberg; William B Isaacs; Jianfeng Xu
Journal:  Cancer       Date:  2013-04-22       Impact factor: 6.860

Review 7.  The addition of chemotherapy in the definitive management of high risk prostate cancer.

Authors:  Matthew J Ferris; Yuan Liu; Jingning Ao; Jim Zhong; Mustafa Abugideiri; Theresa W Gillespie; Bradley C Carthon; Mehmet A Bilen; Omer Kucuk; Ashesh B Jani
Journal:  Urol Oncol       Date:  2018-10-09       Impact factor: 3.498
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.